Advent to sell generic drugmaker Zentiva to GTCR
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Biocon Foundation is also expanding its reach with this first initiative in Channapatna region
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
Maria Soler Nunez appointed as Chief Quality Officer
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Subscribe To Our Newsletter & Stay Updated